Development and optimization of danazol co-crystal loaded tablet to treat endometriosis

Vidya Patil; Shivraj Jadhav; Sunil Mahajan

doi:10.56782/pps.525

Published : 2025-10-01

Vol. 23 No. 4 (2025)

Development and optimization of danazol co-crystal loaded tablet to treat endometriosis

Vidya Patil

Shivraj Jadhav

Sunil Mahajan

DOI: https://doi.org/10.56782/pps.525

Abstract

Objectives: To develop, optimize, and characterize danazol co-crystal-loaded tablets for enhanced solubility and dissolution in order to improve therapeutic efficacy in endometriosis treatment. Methods: Danazol co-crystals were prepared using various co-formers through a solvent evaporation technique and characterized by FTIR, DSC, and XRD. Co-crystals were formulated into tablets using direct compression and optimized through a 3² factorial design, varying sodium croscarmellose (8—24 mg) and PVP K-30 (4—20 mg) concentrations. Formulations were evaluated for pre-compression properties, physical parameters, disintegration, dissolution, and stability. Results: Danazol-malonic acid co-crystals (1:2 ratio) exhibited the highest solubility enhancement (11.42 ± 0.53 μg/mL, 13.76-fold increase). XRD confirmed the formation of a new crystalline phase with distinct peaks at 19° and 21° 2θ. The quadratic models for both disintegration time (R² = 0.9971) and drug release (R² = 0.9483) demonstrated excellent predictive capability. Formulation VF7 (24 mg sodium croscarmellose, 4 mg PVP K-30) was identified as optimal with rapid disintegration (74.0 ± 3.2 seconds) and superior dissolution (83.6 ± 3.4% at 30 minutes, 95.8 ± 2.0% at 60 minutes) compared to the marketed product (75.2 ± 2.7% at 60 minutes). The optimized formulation maintained stability under accelerated conditions (40°C/75% RH) for three months. Conclusion: The optimized danazol co-crystal tablet formulation successfully overcame the solubility and dissolution limitations of this poorly soluble drug, potentially enhancing bioavailability and therapeutic efficacy while reducing dosing frequency for endometriosis patients. This approach presents a promising platform for improving clinical outcomes and patient compliance in endometriosis management.

Keywords:

danazol, co-crystallization, solubility enhancement, factorial design, endometriosis

Similar Articles

Rama Devi Korni, Thanmaisree Bora, Akhil Majji, Jagadeesh Panda, Liquisolid technique for solubility enhancement of a poorly soluble thrombin inhibitor: optimization using design of experiments and artificial neural networks , Prospects in Pharmaceutical Sciences: Vol. 23 No. 3 (2025)
Dr. Ashwini Madgulkar, Dr. Mangesh Bhalekar, Abhishek Kunjir, Maryam Mulla, A SCIENTIFIC EXPLORATION OF CO-AMORPHOUS FORMULATION DRIVEN BY KNOWLEDGE BASED VIRTUAL SCREENING FOR SOLUBILITY AND BIOAVAILABILITY ENHANCEMENT OF DARUNAVIR , Prospects in Pharmaceutical Sciences: No. 2025 (Early Access)
Vijayraj Sonawane, Dhanashree I. Wagh, Sakshi P. Bhamare, Khemchand R. Surana, Deepak D. Sonawane, Sunil K. Mahajan, Enhancing water solubility of a BCS Class II drug using hydrotropy, mixed solvency, co-solvency, and nanosuspension techniques , Prospects in Pharmaceutical Sciences: Vol. 23 No. 4 (2025)
Monika Nijhawan, Bhavana Jidige, Rajeswari Aleti, Sailaja Gunnam, Trapti Saxena, Development and characterization of voriconazole-oxalic acid dihydrate cocrystals for enhanced pharmaceutical performance , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Sailaja Gunnam, Sindhura T, Rajeswari Aleti, Monika Nijhawan, Bi-layer tablets of sitagliptin phosphate & metformin hydrochloride – preparation and evaluation , Prospects in Pharmaceutical Sciences: Vol. 23 No. 3 (2025)
monika nijhawan, Rajeswari Aleti, Sravani Maramwar, Dedipya Goda Srivalli Vangala, Trapti Saxena, Solubility Enhancement of Diacerein Through Liquisolid Technology: A Formulation Perspective , Prospects in Pharmaceutical Sciences: No. 2025 (Early Access)
Rushikesh Mahale, Shivraj Jadhav, Sunil Mahajan, Development and optimization of gastro retentive floating tablets of dapsone for controlled release , Prospects in Pharmaceutical Sciences: Vol. 24 No. 1 (2026)
Ewa Napiórkowska, Overview of cyclodextrins and medicinal products containing cyclodextrins currently registered in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Priya Jagtap, Dr. Reshma Jadhav, Dr. Ashish Jain, Bhavesh Mahajan, Prapti Gawand, Prathamesh Chaudhari, Aishwarya Patil, Quality by design approach in HPLC method development and validation for simultaneous determination of abiraterone acetate and prednisolone with greenness assessment , Prospects in Pharmaceutical Sciences: Vol. 23 No. 3 (2025)
Bartłomiej Pyrak, Tomasz Gubica, Karolina Rogacka-Pyrak, Cyclodextrin nanosponges as bioenhancers of phytochemicals , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)

1 2 3 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Patil, V., Jadhav, S., & Mahajan, S. (2025). Development and optimization of danazol co-crystal loaded tablet to treat endometriosis. Prospects in Pharmaceutical Sciences, 23(4), 220–234. https://doi.org/10.56782/pps.525

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Horan, M. Fertility Preservation in Young Women at Risk of Ovarian Insufficiency Due to Malignancy or Endometriosis. PhD Thesis, University College Dublin, Dublin, Ireland, 2022. Available online: https://researchrepository.ucd.ie/entities/publication/1f82a048-f329-4e50-9629-ffbb5f6ca300 (accessed on 20 May 2025).

2. Missmer, S.A.; Tu, F.F.; Agarwal, S.K.; Chapron, C.; Soliman, A.M.; Chiuve, S.; Eichner, S.; Flores-Caldera, I.; Horne, A.W.; Kimball, A.B.; et al. Impact of Endometriosis on Life-Course Potential: A Narrative Review. Int. J. Gen. Med. 2021, 14, 9–25. DOI: 10.2147/IJGM.S261139

3. Bonavina, G.; Taylor, H.S. Endometriosis-Associated Infertility: From Pathophysiology to Tailored Treatment. Front. Endocrinol. 2022, 13, Art. No: 1020827. DOI: 10.3389/fendo.2022.1020827

4. Adokiye, E.A. Effects of Endometriosis on Quality of Life (Benefit of Combined Hystero-Laparoscopic Surgery on Quality of Life and Fertility Performance in Endometriosis). Doctoral (PhD) Thesis, University of Pécs, Pécs, Hungary, 2024.

5. Donnez, J.; Cacciottola, L.; Squifflet, J.-L.; Dolmans, M.-M. Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review. Drug Des. Dev. Ther. 2023, 17, 369–380. DOI: 10.2147/DDDT.S269976

6. Fuqua, J.S.; Eugster, E.A. History of Puberty: Normal and Precocious. Horm. Res. Paediatr. 2022, 95, 568–578. DOI: 10.1159/000525386

7. Gonçalves, M.D.; Tomiotto-Pellissier, F.; De Matos, R.L.N.; Assolini, J.P.; Da Silva Bortoleti, B.T.; Concato, V.M.; Silva, T.F.; Rafael, J.A.; Pavanelli, W.R.; Conchon-Costa, I.; et al. Recent Advances in Biotransformation by Cunninghamella Species. Curr. Drug Metab. 2021, 22, 1035–1064. DOI: 10.2174/1389200222666211126100023

8. Al-Badr, A.A. Chapter Five – Danazol. In Profiles of Drug Substances, Excipients and Related Methodology; Al-Majed, A.A., Ed.; Academic Press: Cambridge, MA, USA, 2022; Volume 47, pp. 149–326. DOI: 10.1016/bs.podrm.2021.10.005

9. Huang, H.-E.; Lin, K.-M.; Lin, J.-C.; Lin, Y.-T.; He, H.-R.; Wang, Y.-W.; Yu, S.-F.; Chen, J.-F.; Cheng, T.-T. Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review. Pharmaceuticals 2022, 15, Art. No: 1377. DOI: 10.3390/ph15111377

10. Riva, M.; Bosi, A.; Rizzo, L.; Mazzon, F.; Ferrari, S.; Lussana, F.; Borin, L.; Castelli, A.; Cairoli, R.; Barcellini, W.; et al. Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an “Old-Fashioned” Drug Be Effective? HemaSphere 2023, 7, Art. No: e867. DOI: 10.1097/HS9.0000000000000867

11. Nyamba, I.; Sombié, C.B.; Yabré, M.; Zimé-Diawara, H.; Yaméogo, J.; Ouédraogo, S.; Lechanteur, A.; Semdé, R.; Evrard, B. Pharmaceutical Approaches for Enhancing Solubility and Oral Bioavailability of Poorly Soluble Drugs. Eur. J. Pharm. Biopharm. 2024, 204, Art. No: 114513. DOI: 10.1016/j.ejpb.2024.114513

12. Madhuri, G.; Nagaraju, R. An Overview on Novel Particle Engineering Designing: Co-Crystallization Techniques. Int. J. Pharm. Sci. Rev. Res. 2021, 66, 88–101. DOI: 10.47583/ijpsrr.2021.v66i01.015

13. Jadhav, S.P.; Chaudhari, K.R.; Nikam, K.R.; Salunkhe, K.S.; Chaudhari, S.R. Co-Crystal: An Emerging Trend in Pharmaceuticals. Inventi Rapid: NDDS 2012, 2012(3), 1–6.

14. Dhondale, M.R.; Thakor, P.; Nambiar, A.G.; Singh, M.; Agrawal, A.K.; Shastri, N.R.; Kumar, D. Co-Crystallization Approach to Enhance the Stability of Moisture-Sensitive Drugs. Pharmaceutics 2023, 15, Art. No: 189. DOI: 10.3390/pharmaceutics15010189

15. Bhatia, M.; Kumar, A.; Verma, V.; Devi, S. Development of Ketoprofen-p-Aminobenzoic Acid Co-Crystal: Formulation, Characterization, Optimization, and Evaluation. Med. Chem. Res. 2021, 30, 2090–2102. DOI: 10.1007/s00044-021-02794-7

16. Tatsumi, Y.; Shimoyama, Y.; Kazarian, S.G. Analysis of the Dissolution Behavior of Theophylline and Its Cocrystal Using ATR-FTIR Spectroscopic Imaging. Mol. Pharm. 2024, 21, 3233–3239. DOI: 10.1021/acs.molpharmaceut.4c00002

17. Zhang, H.; Zeng, H.; Li, M.; Song, Y.; Tian, S.; Xiong, J.; He, L.; Liu, Y.; Wu, X. Novel Ascorbic Acid Co-Crystal Formulations for Improved Stability. Molecules 2022, 27, Art. No: 7998. DOI: 10.3390/molecules27227998

18. Chettri, A.; Subba, A.; Singh, G.P.; Bag, P.P. Pharmaceutical Co-Crystals: A Green Way to Enhance Drug Stability and Solubility for Improved Therapeutic Efficacy. J. Pharm. Pharmacol. 2024, 76, 1–12. DOI: 10.1093/jpp/rgad097

19. Al-Nimry, S.S.; Khanfar, M.S. Enhancement of the Solubility of Asenapine Maleate Through the Preparation of Co-Crystals. Curr. Drug Deliv. 2022, 19, 788–800. DOI: 10.2174/1567201818666210805154345

20. Huang, Z.; Staufenbiel, S.; Bodmeier, R. Combination of Co-Crystal and Nanocrystal Techniques to Improve the Solubility and Dissolution Rate of Poorly Soluble Drugs. Pharm. Res. 2022, 39, 949–961. DOI: 10.1007/s11095-022-03243-9

21. Ji, X.; Wu, D.; Li, C.; Li, J.; Sun, Q.; Chang, D.; Yin, Q.; Zhou, L.; Xie, C.; Gong, J.; et al. Enhanced Solubility, Dissolution, and Permeability of Abacavir by Salt and Cocrystal Formation. Cryst. Growth Des. 2022, 22, 428–440. DOI: 10.1021/acs.cgd.1c01051

22. Nadh, T.V.H.H.; Kumar, P.S.; Ramana, M.V.; Rao, N.R. Formulation and Optimization of Zolmitriptan Orodispersible Tablets. J. Drug Deliv. Ther. 2021, 11, 50–58. DOI: 10.22270/jddt.v11i3.4703

23. Kumar, S.; Sharma, P. Factorial Design Optimization in Pharmaceutical Formulations. Asian J. Res. Chem. 2021, 14, 245–252.

24. Jadhav, S.; Patil, M. Formulation of Tablet of Ivermectin Co-Crystal for Enhancement of Solubility and Other Physical Properties. Res. J. Pharm. Technol. 2023, 16, 1245–1252.

25. Abdelrahman, H.; Essa, E.; Maghraby, G.E.; Arafa, M. L-Proline as Co-Crystal Forming Amino Acid for Enhanced Dissolution Rate of Lamotrigine: Development of Buccal Tablet. Indones. J. Pharm. 2023, 34, 574–583. DOI: 10.22146/ijp.6867

26. Eidevåg, T.; Thomson, E.S.; Kallin, D.; Casselgren, J.; Rasmuson, A. Angle of Repose of Snow: An Experimental Study on Cohesive Properties. Cold Reg. Sci. Technol. 2022, 194, Art. No: 103470. DOI: 10.1016/j.coldregions.2021.103470

27. Singh, A.; Patel, R. Powder Flow Characterization in Pharmaceutical Manufacturing. Res. J. Pharm. Technol. 2021, 14, 156–162.

28. Al-Dulaimi, A.F.; Al-Kotaji, M.; Abachi, F.T. Paracetamol/Naproxen Co-Crystals: A Simple Way for Improvement of Flowability, Tableting and Dissolution Properties. Iraqi J. Pharm. Sci. 2021, 30, 45–55.

29. Botella-Martínez, C.; Viuda-Martos, M.; Fernández-López, J.A.; Pérez-Alvarez, J.A.; Fernández-López, J. Development of Plant-Based Burgers Using Gelled Emulsions as Fat Source and Beetroot Juice as Colorant. LWT 2022, 172, Art. No: 114193. DOI: 10.1016/j.lwt.2022.114193

30. Simão, J.; Chaudhary, S.A.; Ribeiro, A.J. Implementation of Quality by Design (QbD) for Development of Bilayer Tablets. Eur. J. Pharm. Sci. 2023, 184, Art. No: 106412. DOI: 10.1016/j.ejps.2023.106412

31. Ficzere, M.; Mészáros, L.A.; Kállai-Szabó, N.; Kovács, A.; Antal, I.; Nagy, Z.K.; Galata, D.L. Real-Time Coating Thickness Measurement and Defect Recognition of Film-Coated Tablets with Machine Vision and Deep Learning. Int. J. Pharm. 2022, 623, Art. No: 121957. DOI: 10.1016/j.ijpharm.2022.121957

32. Momeni, M.; Afkanpour, M.; Rakhshani, S.; Mehrabian, A.; Tabesh, H. Prediction Model Based on Artificial Intelligence Techniques for Disintegration Time and Hardness of Fast Disintegrating Tablets. BMC Med. Inform. Decis. Mak. 2024, 24, Art. No: 88. DOI: 10.1186/s12911-024-02485-4

33. Zhao, H.; Yu, Y.; Ni, N.; Zhao, L.; Lin, X.; Wang, Y.; Du, R.; Shen, L. New Parameter for Characterization of Tablet Friability. Int. J. Pharm. 2022, 611, Art. No: 121339. DOI: 10.1016/j.ijpharm.2021.121339

34. Berardi, A.; Bisharat, L.; Quodbach, J.; Abdel Rahim, S.; Perinelli, D.R.; Cespi, M. Advancing the Understanding of Tablet Disintegration Phenomenon. Int. J. Pharm. 2021, 598, Art. No: 120390. DOI: 10.1016/j.ijpharm.2021.120390

35. Farquharson, A.; Gladding, Z.; Ritchie, G.; Shende, C.; Cosgrove, J.; Smith, W.; Brouillette, C.; Farquharson, S. Drug Content Uniformity Using Raman Spectroscopy. Pharmaceutics 2021, 13, Art. No: 309. DOI: 10.3390/pharmaceutics13030309

36. Chakraborty, S.; Mondal, D.S. Green Eco-Friendly Analytical Method Development of Favipiravir. Int. J. Pharm. Investig. 2023, 13, 290–305. DOI: 10.5530/ijpi.13.2.039

37. González-González, O.; Ramirez, I.O.; Ramirez, B.I.; O'Connell, P.; Ballesteros, M.P.; Torrado, J.J.; Serrano, D.R. Drug Stability: ICH versus Accelerated Predictive Stability Studies. Pharmaceutics 2022, 14, Art. No: 2324. DOI: 10.3390/pharmaceutics14112324

38. Parvarinezhad, S.; Salehi, M.; Kubicki, M.; Eshaghi Malekshah, R. Noncovalent Interactions in Co-Crystal of μ-Oxobridged Polymeric Copper(II) Complex. J. Mol. Struct. 2022, 1260, Art. No: 132780. DOI: 10.1016/j.molstruc.2022.132780

39. Rojek, B.; Bartyzel, A.; Leyk, E.; Plenis, A. Arbidol Hydrochloride Compatibility Study Using DSC, FTIR, TGA-FTIR, and PXRD. J. Therm. Anal. Calorim. 2025, 152, 1–15. DOI: 10.1007/s10973-025-14056-4

40. Farag Badawy, S.I.; Ghorab, M.M.; Adeyeye, C.M. Characterization and Bioavailability of Danazol–Hydroxypropyl β-Cyclodextrin Coprecipitates. Int. J. Pharm. 1996, 128, 45–54. DOI: 10.1016/0378-5173(95)04214-8

41. Bhalani, D.V.; Nutan, B.; Kumar, A.; Singh Chandel, A.K. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs. Biomedicines 2022, 10, Art. No: 2055. DOI: 10.3390/biomedicines10092055

42. Han, J.; Li, L.; Su, M.; Heng, W.; Wei, Y.; Gao, Y.; Qian, S. Deaggregation and Crystallization Inhibition in Co-Amorphous Systems. Pharmaceutics 2021, 13, Art. No: 1725. DOI: 10.3390/pharmaceutics13101725

43. Adama, J.C.; Arocha, C.G.; Ogbobe, P.O. Physical Properties of Oil Palm Kernels. Niger. J. Technol. 2022, 41, 365–369. DOI: 10.4314/njt.v41i2.18

44. Kole, S.; Vinchurkar, R.; Gawade, A.; Kuchekar, A. Impact of Co-Crystal Formation on Stability of Camylofin Tablets. Hacet. Univ. J. Fac. Pharm. 2024, 44, 108–123. DOI: 10.52794/hujpharm.1331991

45. Lovanov, R.; Cornilă, A.; Bogdan, C.; Hales, D.; Tomuță, I.; Achim, M.; Tăut, A.; Iman, N.; Casian, T.; Iurian, S. Disintegration and Texture-Related Palatability of Orodispersible Tablets. Eur. J. Pharm. Sci. 2024, 198, Art. No: 106801. DOI: 10.1016/j.ejps.2024.106801

46. Devi, S.; Kumar, A.; Kapoor, A.; Verma, V.; Yadav, S.; Bhatia, M. Ketoprofen–FA Co-Crystal: In Vitro and In Vivo Investigation. AAPS PharmSciTech 2022, 23, Art. No: 101. DOI: 10.1208/s12249-022-02253-5

47. Zarrik, B.; El Amri, A.; Bensalah, J.; Jebli, A.; Lebkiri, A.; Hsissou, R.; Hbaiz, E.M.; Rifi, E.H.; Lebkiri, A. Adsorption of Crystal Violet Using Graphene Oxide Composite. Inorg. Chem. Commun. 2024, 162, Art. No: 112179. DOI: 10.1016/j.inoche.2024.112179

48. Mazloomi, S.; Amarloei, A.; Gholami, F.; Haghighat, G.A.; Badalians Gholikandi, G.; Nourmoradi, H.; Mohammadi, A.A.; Fattahi, M.; Nguyen Le, B. Process Modeling for Metronidazole Removal by ZIF-67 Crystals. Sci. Rep. 2023, 13, Art. No: 14654. DOI: 10.1038/s41598-023-41724-y

49. Ruhil, S.; Dahiya, M.; Kaur, H.; Singh, J. Disintegration Profiling of Rapidly Disintegrating Tablets by Thermal Imaging. Int. J. Pharm. 2022, 611, Art. No: 121283. DOI: 10.1016/j.ijpharm.2021.121283

50. Hu, C.; Zhang, F.; Fan, H. Evaluation of Drug Dissolution in Co-Amorphous and Co-Crystal Systems. AAPS PharmSciTech 2021, 22, Art. No: 21. DOI: 10.1208/s12249-020-01864-0

51. Janilkarn-Urena, I.; Tse, A.; Lin, J.; Tafolla-Aguirre, B.; Idrissova, A.; Zhang, M.; Skinner, S.G.; Mostowfi, N.; Kim, J.; Kalapatapu, N.; et al. Improving Solubility of Pseudo-Hydrophobic Chemicals through Co-Crystal Formulation. PNAS Nexus 2025, 4, Art. No: pgaf007. DOI: 10.1093/pnasnexus/pgaf007

52. Orszulak, L.; Włodarczyk, P.; Hachuła, B.; Lamrani, T.; Jurkiewicz, K.; Tarnacka, M.; Hreczka, M.; Kamiński, K.; Kamińska, E. Inhibition of Naproxen Crystallization by Polymers. Eur. J. Pharm. Biopharm. 2025, 207, Art. No: 114581. DOI: 10.1016/j.ejpb.2024.114581

53. Jadhav, S.P.; Ahire, S.M.; Shewale, V.V.; Patil, C.D.; Pagar, R.Y.; Sonawane, D.D.; et al. Formulation of Tablet of Nifedipine Co-Crystal for Enhancement of Solubility. Biosci. Biotechnol. Res. Asia 2025, 22(1), 191–200. DOI: 10.13005/bbra/3353

Vidya Patil

vidyapatil03112001@gmail.com

Affiliation:

a:1:{s:5:"en_US";s:35:"Divine College of Pharmacy, Satana ";} India

Development and optimization of danazol co-crystal loaded tablet to treat endometriosis

Vidya Patil

Shivraj Jadhav

Sunil Mahajan

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Vidya Patil

Shivraj Jadhav

Sunil Mahajan